Biomea Fusion Inc reports results for the quarter ended March 31 - Earnings Summary
06/05/2025 18:07
Biomea Fusion Inc BMEA.OQ reported a quarterly adjusted loss of 80 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.09. The mean expectation of five analysts for the quarter was for a loss of 61 cents per share. Wall Street expected results to range from -85 cents to -23 cents per share. Reported revenue was zero; analysts expected zero. Biomea Fusion Inc's reported EPS for the quarter was a loss of 80 cents. The company reported a quarterly loss of $29.26 million. Biomea Fusion Inc shares had fallen by 6.1% this quarter and lost 48.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 34.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Biomea Fusion Inc is $18.00 This summary was machine generated from LSEG data May 6 at 05:07 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.61 | -0.80 | Missed |
| Dec. 31 2024 | -0.92 | -0.81 | Beat |
| Sep. 30 2024 | -0.95 | -0.91 | Beat |
| Jun. 30 2024 | -1.07 | -1.03 | Beat |
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes